Total submissions: 5
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Baylor Genetics | RCV000850605 | SCV000992836 | likely pathogenic | Intellectual disability, autosomal dominant 16 | 2017-12-31 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV001016361 | SCV001177309 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-08-31 | criteria provided, single submitter | clinical testing | The p.V902M variant (also known as c.2704G>A), located in coding exon 18 of the SMARCA4 gene, results from a G to A substitution at nucleotide position 2704. The valine at codon 902 is replaced by methionine, an amino acid with highly similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Missense and in-frame variants in SMARCA4 are known to cause neurodevelopmental disorders; however, such associations with rhabdoid tumor predisposition syndrome including small cell carcinoma of the ovary-hypercalcemic type (SCCOHT) are exceedingly rare (Kosho T et al. Am J Med Genet C Semin Med Genet. 2014 Sep;166C(3):262-75; Jelinic P et al. Nat Genet. 2014 May;46(5):424-6). Based on the supporting evidence, the association of this alteration with Coffin-Siris syndrome is unknown; however, the association of this alteration with rhabdoid tumor predisposition syndrome is unlikely. |
| Baylor Genetics | RCV001533128 | SCV001748948 | likely pathogenic | SMARCA4-related BAFopathy | 2021-06-10 | criteria provided, single submitter | clinical testing | |
| Genome- |
RCV000850605 | SCV002056183 | uncertain significance | Intellectual disability, autosomal dominant 16 | 2021-07-15 | criteria provided, single submitter | clinical testing | |
| Invitae | RCV003768619 | SCV004640862 | uncertain significance | Rhabdoid tumor predisposition syndrome 2 | 2022-12-20 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt SMARCA4 protein function. ClinVar contains an entry for this variant (Variation ID: 689790). This missense change has been observed in individual(s) with unspecified Mendelian disease (PMID: 31216405). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 902 of the SMARCA4 protein (p.Val902Met). |